title: Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
abstract: Immune checkpoint inhibitors are considered standard second-line treatment in advanced non-small cell lung cancer patients. This strategy has also become standard in first-line setting for a subgroup of patients with strongly positive PD-L1 tumors; therefore, PD-L1 status might be considered a new biomarker that deserves upfront testing. New combinations of immune checkpoint inhibitors and with chemotherapy have been tested in first-line treatment. However, some questions remain unanswered such as the best treatment strategy or the real upfront efficacy of these therapeutic strategies in the whole lung cancer population. In this review we summarize the main results in the first-line setting of recent phase III trials with immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
authors.affiliation: Hospital Vall d'Hebron, Medical Oncology Department, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: jremon@vhio.net.
authors.forename: J
authors.initials: J
authors.lastname: Remon
authors.affiliation: Hospital Vall d'Hebron, Medical Oncology Department, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: npardo@vhio.net.
authors.forename: N
authors.initials: N
authors.lastname: Pardo
authors.affiliation: Hospital Vall d'Hebron, Medical Oncology Department, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: anamariamdc@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Martinez-Martí
authors.affiliation: Hospital Vall d'Hebron, Medical Oncology Department, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: scdedres@vhebron.net.
authors.forename: S
authors.initials: S
authors.lastname: Cedrés
authors.affiliation: Hospital Vall d'Hebron, Medical Oncology Department, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: alnavarro@vhebron.net.
authors.forename: A
authors.initials: A
authors.lastname: Navarro
authors.affiliation: Hospital Vall d'Hebron, Medical Oncology Department, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: anamariamdc@gmail.com.
authors.forename: A M
authors.initials: AM
authors.lastname: Martinez de Castro
authors.affiliation: Hospital Vall d'Hebron, Medical Oncology Department, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: efelip@vhio.net.
authors.forename: E
authors.initials: E
authors.lastname: Felip
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab
keywords: First-line; Immunotherapy; Nivolumab; Non-small cell lung cancer; Pembrolizumab